Assessing the effect of caffeine on attention in patients with and without dementia: A double blind, randomised, cross over trial

orth Bristol NHS Trust (UK)0 个研究点目标入组 40 人开始时间: 2014年6月6日最近更新: 2019年2月11日

适应症

试验速览

2016 results presented at ABN Annual Meeting 2016 https://jnnp.bmj.com/content/87/12/e1.201

•1. Patients with dementia with Lewy bodies or Parkinson's disease dementia fulfilling standard diagnostic criteria who retain capacity to consent to research, in keeping with the Mental Capacity Act 2005
•2. Patients on or off cholinesterase inhibitors or memantine as long as stable on medication for 3 months or more
•3. An adequate level of communication in written and verbal English

•1. Patients with alternative neurodegenerative diseases or other condition likely to interfere with test performance (e.g. chronic pain, stroke)
•2. Patients on medication likely to interfere with cognitive performance that has been changed in the last 3 months
•3. The tests of attention in this trial require a working knowledge of English, good vision and the ability to walk independently (with or without walking aids) and we will therefore exclude patients without sufficient English language skills, those with poor vision and those who cannot walk independently.
•4. Patients taking caffeine containing medication or foodstuffs with greater than 15mg caffeine over a day who do not wish to cease ingestion
•5. If a patient loses capacity to consent during the trial they will be withdrawn

发起方

orth Bristol NHS Trust (UK)